JP7444995B2 - 超微粒化合物およびその製造 - Google Patents
超微粒化合物およびその製造 Download PDFInfo
- Publication number
- JP7444995B2 JP7444995B2 JP2022538055A JP2022538055A JP7444995B2 JP 7444995 B2 JP7444995 B2 JP 7444995B2 JP 2022538055 A JP2022538055 A JP 2022538055A JP 2022538055 A JP2022538055 A JP 2022538055A JP 7444995 B2 JP7444995 B2 JP 7444995B2
- Authority
- JP
- Japan
- Prior art keywords
- cyclodextrin
- api
- acetylated
- encapsulated
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 150000001875 compounds Chemical class 0.000 title description 18
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 178
- 229920000858 Cyclodextrin Polymers 0.000 claims description 119
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 114
- 239000003557 cannabinoid Substances 0.000 claims description 67
- 229930003827 cannabinoid Natural products 0.000 claims description 67
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 67
- 238000000034 method Methods 0.000 claims description 61
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 57
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 47
- 239000002245 particle Substances 0.000 claims description 47
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 46
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 45
- 229950011318 cannabidiol Drugs 0.000 claims description 45
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 45
- 239000001569 carbon dioxide Substances 0.000 claims description 43
- 239000002105 nanoparticle Substances 0.000 claims description 41
- 239000007788 liquid Substances 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 26
- 229940097362 cyclodextrins Drugs 0.000 claims description 26
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 26
- 229940065144 cannabinoids Drugs 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 18
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 18
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 16
- 239000000725 suspension Substances 0.000 claims description 13
- 239000001116 FEMA 4028 Substances 0.000 claims description 12
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 12
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 12
- 229960004853 betadex Drugs 0.000 claims description 12
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 11
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 11
- 230000001337 psychedelic effect Effects 0.000 claims description 11
- 238000005086 pumping Methods 0.000 claims description 11
- 238000005507 spraying Methods 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 9
- 239000003380 propellant Substances 0.000 claims description 9
- UCONUSSAWGCZMV-HZPDHXFCSA-N Delta(9)-tetrahydrocannabinolic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCCCC)C(C(O)=O)=C1O UCONUSSAWGCZMV-HZPDHXFCSA-N 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- TWKHUZXSTKISQC-UHFFFAOYSA-N 2-(5-methyl-2-prop-1-en-2-ylphenyl)-5-pentylbenzene-1,3-diol Chemical compound OC1=CC(CCCCC)=CC(O)=C1C1=CC(C)=CC=C1C(C)=C TWKHUZXSTKISQC-UHFFFAOYSA-N 0.000 claims description 7
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 claims description 7
- SEEZIOZEUUMJME-FOWTUZBSSA-N cannabigerolic acid Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-FOWTUZBSSA-N 0.000 claims description 7
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 claims description 6
- 241000218236 Cannabis Species 0.000 claims description 6
- IGHTZQUIFGUJTG-QSMXQIJUSA-N O1C2=CC(CCCCC)=CC(O)=C2[C@H]2C(C)(C)[C@@H]3[C@H]2[C@@]1(C)CC3 Chemical compound O1C2=CC(CCCCC)=CC(O)=C2[C@H]2C(C)(C)[C@@H]3[C@H]2[C@@]1(C)CC3 IGHTZQUIFGUJTG-QSMXQIJUSA-N 0.000 claims description 6
- 238000009826 distribution Methods 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 235000013334 alcoholic beverage Nutrition 0.000 claims description 5
- 239000003146 anticoagulant agent Substances 0.000 claims description 5
- 229940127219 anticoagulant drug Drugs 0.000 claims description 5
- 239000001961 anticonvulsive agent Substances 0.000 claims description 5
- 239000000935 antidepressant agent Substances 0.000 claims description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 5
- 239000003158 myorelaxant agent Substances 0.000 claims description 5
- 239000012716 precipitator Substances 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 4
- HRHJHXJQMNWQTF-UHFFFAOYSA-N cannabichromenic acid Chemical compound O1C(C)(CCC=C(C)C)C=CC2=C1C=C(CCCCC)C(C(O)=O)=C2O HRHJHXJQMNWQTF-UHFFFAOYSA-N 0.000 claims description 4
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 claims description 4
- 235000019520 non-alcoholic beverage Nutrition 0.000 claims description 4
- SPCIYGNTAMCTRO-UHFFFAOYSA-N Psilocine Natural products C1=CC(O)=C2C(CCN(C)C)=CNC2=C1 SPCIYGNTAMCTRO-UHFFFAOYSA-N 0.000 claims description 3
- QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 claims description 3
- 230000003444 anaesthetic effect Effects 0.000 claims description 3
- 230000000202 analgesic effect Effects 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 230000001773 anti-convulsant effect Effects 0.000 claims description 3
- 230000001430 anti-depressive effect Effects 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 229940005513 antidepressants Drugs 0.000 claims description 3
- 229960003965 antiepileptics Drugs 0.000 claims description 3
- 239000002270 dispersing agent Substances 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 238000003801 milling Methods 0.000 claims description 3
- ZBWSBXGHYDWMAK-UHFFFAOYSA-N psilocin Chemical compound C1=CC=C(O)[C]2C(CCN(C)C)=CN=C21 ZBWSBXGHYDWMAK-UHFFFAOYSA-N 0.000 claims description 3
- QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 2
- FAVCTJGKHFHFHJ-GXDHUFHOSA-N 3-[(2e)-3,7-dimethylocta-2,6-dienyl]-2,4-dihydroxy-6-propylbenzoic acid Chemical compound CCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1C(O)=O FAVCTJGKHFHFHJ-GXDHUFHOSA-N 0.000 claims 1
- FAVCTJGKHFHFHJ-UHFFFAOYSA-N CBGVA Natural products CCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1C(O)=O FAVCTJGKHFHFHJ-UHFFFAOYSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 description 74
- 239000007789 gas Substances 0.000 description 22
- 229960004242 dronabinol Drugs 0.000 description 16
- 239000012530 fluid Substances 0.000 description 16
- 238000000605 extraction Methods 0.000 description 15
- 238000011282 treatment Methods 0.000 description 14
- 239000000523 sample Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- AAXZFUQLLRMVOG-UHFFFAOYSA-N 2-methyl-2-(4-methylpent-3-enyl)-7-propylchromen-5-ol Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCC)=CC(O)=C21 AAXZFUQLLRMVOG-UHFFFAOYSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- -1 cyclic oligosaccharides Chemical class 0.000 description 7
- 239000012467 final product Substances 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 description 6
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000003929 acidic solution Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000003196 psychodysleptic agent Substances 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- CZXWOKHVLNYAHI-LSDHHAIUSA-N 2,4-dihydroxy-3-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-6-propylbenzoic acid Chemical compound OC1=C(C(O)=O)C(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 CZXWOKHVLNYAHI-LSDHHAIUSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 150000003505 terpenes Chemical class 0.000 description 3
- 235000007586 terpenes Nutrition 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- KXKOBIRSQLNUPS-UHFFFAOYSA-N 1-hydroxy-6,6,9-trimethyl-3-pentylbenzo[c]chromene-2-carboxylic acid Chemical compound O1C(C)(C)C2=CC=C(C)C=C2C2=C1C=C(CCCCC)C(C(O)=O)=C2O KXKOBIRSQLNUPS-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- YJYIDZLGVYOPGU-XNTDXEJSSA-N 2-[(2e)-3,7-dimethylocta-2,6-dienyl]-5-propylbenzene-1,3-diol Chemical compound CCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-XNTDXEJSSA-N 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 description 2
- KASVLYINZPAMNS-UHFFFAOYSA-N Cannabigerol monomethylether Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(OC)=C1 KASVLYINZPAMNS-UHFFFAOYSA-N 0.000 description 2
- SEEZIOZEUUMJME-VBKFSLOCSA-N Cannabigerolic acid Natural products CCCCCC1=CC(O)=C(C\C=C(\C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-VBKFSLOCSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000002879 Lewis base Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- YJYIDZLGVYOPGU-UHFFFAOYSA-N cannabigeroldivarin Natural products CCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-UHFFFAOYSA-N 0.000 description 2
- SEEZIOZEUUMJME-UHFFFAOYSA-N cannabinerolic acid Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-UHFFFAOYSA-N 0.000 description 2
- 229960003453 cannabinol Drugs 0.000 description 2
- SVTKBAIRFMXQQF-UHFFFAOYSA-N cannabivarin Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCC)C=C3OC(C)(C)C2=C1 SVTKBAIRFMXQQF-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229930002875 chlorophyll Natural products 0.000 description 2
- 235000019804 chlorophyll Nutrition 0.000 description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000006114 decarboxylation reaction Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229920000591 gum Polymers 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000007527 lewis bases Chemical class 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940035363 muscle relaxants Drugs 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000021055 solid food Nutrition 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- YOVRGSHRZRJTLZ-UHFFFAOYSA-N Delta9-THCA Natural products C1=C(C(O)=O)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 YOVRGSHRZRJTLZ-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 244000213578 camo Species 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- ORIYPICUSOGUOA-UHFFFAOYSA-N cannabidiol propyl analogue Natural products CCCc1cc(O)c(C2CC(=CCC2C(=C)C)C)c(O)c1 ORIYPICUSOGUOA-UHFFFAOYSA-N 0.000 description 1
- 229930191614 cannabinolic acid Natural products 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000000380 hallucinogen Substances 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000199 molecular distillation Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000001046 rapid expansion of supercritical solution Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000010963 scalable process Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 238000000526 short-path distillation Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229940100515 sorbitan Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 229940116411 terpineol Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 150000008501 α-D-glucopyranosides Chemical group 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5112—Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Non-Alcoholic Beverages (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Alcoholic Beverages (AREA)
- General Preparation And Processing Of Foods (AREA)
- Preparation Of Fruits And Vegetables (AREA)
- Tea And Coffee (AREA)
- Seeds, Soups, And Other Foods (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
Description
本出願は、2019年10月21日に出願された米国仮出願第62/923,726号、および2019年11月1日に出願された米国仮出願第62/929,455号の優先権を主張し、それらの内容は、参照により、それらの全体が組み込まれる。
高い生物学的利用能を有する純粋な親油性API化合物の製造のための効率的なプロセスの開発は、水性および酸性条件におけるAPIの低い溶解度によってこれまでに妨げられてきた。その結果、従来の親油性APIの調製および純化は、多くの場合、有毒な有機溶媒の使用を必要とする、時間のかかるプロセスである。加えて、現在利用可能な方法によって製造されるAPIは、純度の欠如に悩まされ、低い生物学的利用能を有する。
開示される方法を実施するための例示的な装置の図を、図6、7および8に示す。しかしながら、当該技術分野で既知の任意の装置、システム、または機器を使用して、本明細書で提供される方法を実施することができる。
加えて、本明細書では、開示される方法によって生成される安定した食用、吸入可能、可溶性、または飲用可能な医薬グレードのシクロデキストリン封入活性医薬成分が提供される。安定した食用、吸入可能、可溶性、または飲用可能な医薬グレードのシクロデキストリン封入活性医薬成分は、99.9%の純度、および非シクロデキストリン封入活性医薬成分の製剤と比較して200%の増加した生物学的利用能を有する。活性医薬成分は、カンナビノイド、サイケデリック、鎮痛剤、麻酔剤、抗炎症剤、抗細菌剤、抗ウイルス剤、抗凝固剤、抗けいれん剤、抗うつ剤、または筋弛緩剤であり得る。
カンナビノイド前駆体のカンナビゲロール酸(CBGA)およびカンナビゲロバリン酸(CBGVA)を、カンナビス植物から抽出することにより得たか、または商業的に購入した。カンナビノイドであるテトラヒドロカンナビノール酸(THCA)、カンナビノール酸(CBDA)、カンナビクロメン酸(CBCA)、(-)-トランス-Δ9-テトラヒドロカンナビノール酸(Δ9-THCA)、テトラヒドロカンナビバリン酸(THCVA)、カンナビクロメバリン酸(CBCVA)およびカンナビジバリン酸(CBDVA)を、有機溶媒抽出、蒸気または超臨界流体抽出によってCannabis sativa植物から抽出した。カンナビノイドの中性形態であるテトラヒドロカンナビノール(THC)、カンナビジオール(CBD)、(-)-トランス-Δ9-テトラヒドロカンナビノール(Δ9-THC)、(-)-トランス-Δ9-テトラヒドロカンナビフェロール(Δ9-THCP)、カンナビゲロール(CBG)、カンナビクロメン(CBC)、カンナビシクロール(CBL)、カンナビジオール(CBD)、カンナビノジオール(CBND)、およびカンナビノール(CBN)を、加熱、乾燥、または燃焼によるそれらの対応する酸性形態の脱炭酸によって得た。加熱による脱炭酸のために、カンナビノイド抽出物を溶融するまで95℃で約20分間加熱し、次いで、冷凍庫で約15分間冷却した。
本明細書に開示されるように、微粉ナノ粒子を作製した。カンナビノイド添加前にCO2を用いて洗浄することにより、湿度の影響を最小限に抑えるようにシステムを最適化し、25秒間の再加圧サイクルを用いて0.5秒間に圧力放出プロセスを最適化して、ノズルの凍結を防止し、均一性および再現性を確保した。
カンナビノイドの水への溶解度を増加させるために、実施例1に記載のように生成されたカンナビノイド抽出物、蒸留物および単離物を、α-シクロデキストリンまたはβ-シクロデキストリンと1:0.5~1:10の範囲のカンナビノイド:シクロデキストリンのモル比で組み合わせ、10mlの反応器チャンバに添加した。超臨界CO2を1,000psiの圧力で反応チャンバ内にポンプで送り、反応器チャンバを40℃に加熱し、圧力を3,500psiに上昇させた。得られた溶液を、5μmのノズルを介して0.5秒間バーストで放出した。シクロデキストリンは、プロセス条件下で不溶性であることを見出した。
アセチル化シクロデキストリンを有するカンナビノイド複合体を、1:0.5~1:10の範囲のカンナビノイド:シクロデキストリンのモル比で実施例3に記載されるように調製し、各々を10mlの反応器チャンバに添加した。カンナビノイド-シクロデキストリン複合体を、3500psiの圧力および40℃の温度で超臨界流体中に溶解させた。この溶液を、5ミクロンのノズルを介して、管状排気を備える19リットルの膨張チャンバ内へと減圧させ、微粒子の最大回収を確実にした。図2Aおよび2Bは、カンナビノイド:シクロデキストリンのモル比が1:2.5w/w(100mgのα-シクロデキストリンと複合体化された250mgのCBD)のα-シクロデキストリンと複合体化されたCBD蒸留物の粒子の32倍の倍率および200倍の倍率をそれぞれ示す。生成されたCBDナノ粒子は、100nm~40μmの粒子サイズを有する球状形態を示し、アセチル化シクロデキストリンの添加は、図2Aおよび2Bに示されるように、処理後に再懸濁しない微粉末を生成し、CBD化合物のAACD環内への統合を示唆した。
実施例4に記載のように得られたカンナビノイド超微細ナノ粒子の生物学的利用能を、模擬胃条件における微粉ナノ粒子の溶解度を目視評価することによって調査した。0.5gのNaClを0.155MのHCl水溶液に添加し、胃酸条件に似せた。10mgの微粉ナノ粒子、10mgの結晶形態の単離物、および10mgの蒸留物を各々、10mlの酸性溶液を含有するバイアルに入れ、37℃で10時間インキュベートした。10時間の期間の終わりに、調製物の最小限の溶解度のみが観察された。10mlの酸性溶液を追加で添加し、混合物を37℃で10時間以上インキュベートした。20時間の期間の終わりに、カンナビノイドナノ粒子は酸性溶液中に溶解した。対照的に、結晶形態の単離物および蒸留物は、完全な不溶性を示した(図3~5)。
UV検出器を備えた高性能液体クロマトグラフィー(HPLC)分離器を使用して、水中のカンナビノイド単離物(対照試料)と比較して、実施例4に記載のように得られたカンナビノイド超微細ナノ粒子(試験試料)の相対的な生物学的利用能試験を実施し、各試料中のCBDの濃度を決定した。対照試料を、1mlの各試料を0.45μmの濾過器に通して2mlのHPLCバイアル内へと濾過することによって調製し、1mlのメタノール(MeOH)を各試料バイアルに添加した。HPLC移動相は、65%のアセトニトリルおよび35%の水から構成された。1分間当たり1mlの流量は、約4.5分間後にCBDの溶出をもたらした。
APIの水への溶解度を増加させるために、実施例1に記載のようなカンナビノイド蒸留物を様々なシクロデキストリンと組み合わせ、得られた混合物を高圧反応器に入れた。液化CO2を、反応器の圧力が5,000psiに達するまで反応器内にポンプで送った。混合物を反応器内で30分間撹拌し、シクロデキストリン封入カンナビノイドを作製した。次いで、混合物をサイクロン内にスプレーして、CO2を蒸発させ、シクロデキストリン封入カンナビノイド乾燥粉末を得た。回収したCO2を、将来的な使用のために緩衝タンクに保管した。以下の表1は、各試料中のカンナビノイド量のパーセンテージを示す。表1はまた、シクロデキストリン封入カンナビノイドナノ粒子中のカンナビノイド量の平均パーセンテージが、標準的な非シクロデキストリン封入カンナビノイドナノ粒子中のカンナビノイド量の平均よりも10倍高かったことを示す。
実施例7から得られた試料を溶解させることによって、溶解プロファイルを決定した。商業的なTHC油(Reign Drops、THC 30mg/ml)を標準対照として使用した。等量のカンナビノイド(40mg)を含有する各試料を、200mlの蒸留水に溶解させた。温度を50℃で一定に保持した。
パンの酵母(Saccharomyces cerevisiae)を使用して、膜を横断する輸送速度を測定し、2時間の期間にわたり、非封入THC吸収と比較して、シクロデキストリン封入カンナビノイドの生体内への取り込みを評価した。
Claims (9)
- 99.9%の純度、および非シクロデキストリン封入活性医薬成分の製剤と比較して200%の増加した生物学的利用能を有する、安定した食用、吸入可能、可溶性、または飲用可能な医薬グレードの高度に生物学的利用可能かつ安定した超微細シクロデキストリン封入水不溶性活性医薬成分を製造する方法であって、
前記水不溶性活性医薬成分が、カンナビノイド、サイケデリック、鎮痛剤、麻酔剤、抗炎症剤、抗細菌剤、抗ウイルス剤、抗凝固剤、抗けいれん剤、抗うつ剤、または筋弛緩剤であり、
前記方法が、
(a)前記活性医薬成分(API)を超臨界、亜臨界、高圧ガスまたは液体の二酸化炭素中に溶解させて、API溶液を形成することと、
(b)1つ以上のシクロデキストリンを前記API溶液に添加することと、
(c)設定された圧力および設定された温度で所定の期間にわたって前記二酸化炭素をポンプで送ることと、
(d)前記API溶液を減圧させることと、
(e)前記API溶液をスプレーして、それによって、安定した食用、吸入可能、可溶性、または飲用可能な医薬グレードの高度に生物学的利用可能かつ安定した超微細シクロデキストリン封入水不溶性活性医薬成分を製造することと、を含む、方法。 - 前記医薬グレードの高度に生物学的利用可能な微粉シクロデキストリン封入活性医薬成分が、100nm~40μmの平均粒子サイズ、および前記平均粒子サイズの約1%~約50%以内のサイズ分布を有する吸入可能な超微細ナノ粒子の形態にあり、
前記方法が、
(i)反応チャンバ内にて前記APIと、1つ以上のアセチル化シクロデキストリンとを、超臨界、亜臨界、高圧ガスまたは液体の二酸化炭素中に溶解させることと、
(ii)設定された圧力および設定された温度で所定の期間にわたって前記二酸化炭素をポンプで送り、アセチル化シクロデキストリン封入API溶液を得ることと、
(iii)前記アセチル化シクロデキストリン封入API溶液を減圧させることと、
(iv)前記アセチル化シクロデキストリン封入API溶液を加熱された沈殿器内へとノズルを介してスプレーして、アセチル化シクロデキストリン封入活性医薬成分の吸入可能な超微細ナノ粒子を得ることと、
(v)アセチル化シクロデキストリン封入活性医薬成分の前記吸入可能な超微細ナノ粒子を粒子サイズによって収集および選別することと、を含む、請求項1に記載の方法。 - 前記医薬グレードの高度に生物学的利用可能かつ安定した超微細シクロデキストリン封入活性医薬成分が、吸入可能な乾燥粉末の形態にあり、
前記方法が、
(i)親水性シクロデキストリンを、100nm~5μmの平均粒子サイズを有する粒子に粉砕することと、
(ii)前記反応チャンバ内にて前記APIと、1つ以上のアセチル化シクロデキストリンとを、超臨界、亜臨界、高圧ガスまたは液体の二酸化炭素中に溶解させることと、
(iii)設定された圧力および設定された温度で所定の期間にわたって前記二酸化炭素をポンプで送り、アセチル化シクロデキストリン封入API溶液を得ることと、
(iv)前記アセチル化シクロデキストリン封入API溶液を減圧させることと、
(v)前記アセチル化シクロデキストリン封入API溶液に親水性シクロデキストリン粒子を添加して、親水性シクロデキストリン懸濁液-アセチル化シクロデキストリン封入API溶液混合物を作製することと、
(vi)前記混合物を加熱された沈殿器内へとノズルを介してスプレーして、シクロデキストリン封入活性医薬成分の吸入可能な超微細乾燥粉末を得ることと、
(vii)前記シクロデキストリン封入活性医薬成分の前記吸入可能な超微細乾燥粉末を粒子サイズによって収集および選別することと、を含む、請求項1に記載の方法。 - 前記医薬グレードの高度に生物学的利用可能かつ安定した超微細シクロデキストリン封入活性医薬成分が、可溶性または飲用可能な溶液または懸濁液の形態にあり、
前記方法が、
(i)制御された圧力および温度で親水性シクロデキストリンを親水性液体中に溶解させて、親水性シクロデキストリン水溶液を形成することと、
(ii)反応チャンバ内にて前記APIを超臨界、亜臨界、高圧ガスまたは液体の二酸化炭素中に溶解させることと、
(iii)設定された圧力および設定された温度で所定の期間にわたって前記二酸化炭素をポンプで送り、API溶液を得ることと、
(iv)前記API溶液を減圧させることと、
(v)前記API溶液を前記親水性シクロデキストリン水溶液中にノズルを介してスプレーして、親水性シクロデキストリン封入活性医薬成分の飲用可能な溶液または懸濁液を得ることと、を含む、請求項1に記載の方法。 - 前記超臨界、亜臨界、高圧ガスまたは液体の二酸化炭素が、賦形剤、乳化剤または分散剤を含み、前記方法が、(vi)二酸化炭素をガスに変換することと、(vii)超臨界、亜臨界、高圧ガスまたは液体状態を達成するために二酸化炭素ガスを濾過および加圧することと、(viii)前記反応チャンバ内で二酸化炭素を再循環させることと、をさらに含む、請求項1に記載の方法。
- 前記サイケデリックが、プシロシンまたはプシロシビンである、請求項1に記載の方法。
- 前記カンナビノイドが、カンナビゲロール酸(CBGA)、カンナビゲロバリン酸(CBGVA、テトラヒドロカンナビノール酸(THCA)、カンナビクロメン酸(CBCA)、カンナビジオール酸(CBDA)、テトラヒドロカンナビバリン酸(THCVA)、カンナビクロメバリン酸(CBCVA)、カンナビジバリン酸(CBDVA)、(-)-トランス-Δ9-テトラヒドロカンナビノール(Δ9-THC)、(-)-トランス-Δ9-テトラヒドロカンナビフェロール(Δ9-THCP)、カンナビゲロール(CBG)、カンナビクロメン(CBC)、カンナビシクロール(CBL)、カンナビジオール(CBD)、カンナビノジオール(CBND)、カンナビノール(CBN)のうちの1つ以上、またはそれらの任意の混合物を含み、および
前記1つ以上のカンナビノイドが、処理する前に、抽出物、蒸留物、2回純化蒸留物、3回純化蒸留物、または部分的に精製された単離物の形態にある、
請求項1に記載の方法。 - 前記1つ以上のアセチル化シクロデキストリンが、アセチル化α-シクロデキストリン、アセチル化β-シクロデキストリン、アセチル化γ-シクロデキストリン、またはそれらの任意の混合物を含み、および
前記APIおよび前記1つ以上のアセチル化シクロデキストリンが、1:0.5~1:10の範囲のAPI:アセチル化シクロデキストリンのモル比にあるか、または前記API:アセチル化シクロデキストリンのモル比が、1:0.5、1:0.75、1:1、1:1.5、1:2、1:2.5、1:3、1:3.5、1:4、1:4.5、1:5、1:5.5、1:6、1:6.5、1:7、1:7.5、1:8、1:8.5、1:9、1:9.5、もしくは1:10である、
請求項2に記載の方法。 - 前記親水性シクロデキストリンが、親水性α-シクロデキストリン、親水性β-シクロデキストリン、親水性γ-シクロデキストリン、またはそれらの任意の混合物を含み、
前記親水性液体が、任意選択的に賦形剤若しくは乳化剤を含有する、水、ジュース、シロップ、牛乳、またはアルコールもしくはノンアルコール飲料である、
請求項4に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962923726P | 2019-10-21 | 2019-10-21 | |
US62/923,726 | 2019-10-21 | ||
US201962929455P | 2019-11-01 | 2019-11-01 | |
US62/929,455 | 2019-11-01 | ||
PCT/US2020/056731 WO2021081140A1 (en) | 2019-10-21 | 2020-10-21 | Superfine compounds and production thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022545986A JP2022545986A (ja) | 2022-11-01 |
JP7444995B2 true JP7444995B2 (ja) | 2024-03-06 |
Family
ID=75620236
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022538055A Active JP7444995B2 (ja) | 2019-10-21 | 2020-10-21 | 超微粒化合物およびその製造 |
JP2022550656A Pending JP2022554420A (ja) | 2019-10-21 | 2020-10-21 | 超微粒化合物を含む組成物およびその製造 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022550656A Pending JP2022554420A (ja) | 2019-10-21 | 2020-10-21 | 超微粒化合物を含む組成物およびその製造 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220387339A1 (ja) |
EP (2) | EP4048242A1 (ja) |
JP (2) | JP7444995B2 (ja) |
KR (2) | KR20220110730A (ja) |
CN (2) | CN114630658A (ja) |
AU (2) | AU2020370165A1 (ja) |
BR (2) | BR112022007605A2 (ja) |
CA (2) | CA3158415A1 (ja) |
IL (2) | IL292404A (ja) |
MX (2) | MX2022004738A (ja) |
WO (2) | WO2021081140A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230219889A1 (en) | 2020-05-19 | 2023-07-13 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
WO2023053090A1 (en) * | 2021-10-01 | 2023-04-06 | Optimi Health Corp. | Extraction technique |
WO2023161645A2 (en) * | 2022-02-24 | 2023-08-31 | Grow Biotech Plc | Pharmaceutical compositions for vaporization and inhalation |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004511530A (ja) | 2000-10-19 | 2004-04-15 | セパレックス | ホスト分子に包接された活性成分からなる微細粒子の製造方法 |
US20050153931A1 (en) | 2002-02-20 | 2005-07-14 | Pedipharm Oy | Novel natural cyclodextrin complexes |
JP2006524670A (ja) | 2003-04-25 | 2006-11-02 | ピエール、ファーブル、メディカマン | 分子複合体の調製のための方法 |
JP2010505605A (ja) | 2006-10-06 | 2010-02-25 | ニューサウス イノベーションズ ピーティーワイ リミテッド | 粒子の形成 |
JP2010522730A (ja) | 2007-03-28 | 2010-07-08 | ピエール ファーブル メディカモン | イブプロフェン、シクロデキストリンと第3の作用物質の錯体、および薬学におけるその利用方法 |
US20190038995A1 (en) | 2017-01-19 | 2019-02-07 | Metamorphic Alchemy & Distillations, Inc. | Method for removing contaminants from cannabinoid distillates |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9726916D0 (en) * | 1997-12-19 | 1998-02-18 | Danbiosyst Uk | Nasal formulation |
DE60117777T2 (de) * | 2000-05-11 | 2006-08-17 | Eastman Chemical Co., Kingsport | Acylierte zyclodextrin guest-inklusion komplexe |
AU2002345758A1 (en) * | 2001-06-22 | 2003-01-08 | Raveendran Poovathinthodiyil | Renewable, carbohydrate based co2-philes |
FI20020333A0 (fi) * | 2002-02-20 | 2002-02-20 | Tomi Jaervinen | Metyloidun syklodekstriinin uudet kompleksit |
US6946150B2 (en) * | 2002-08-14 | 2005-09-20 | Gw Pharma Limited | Pharmaceutical formulation |
TWI369203B (en) * | 2004-11-22 | 2012-08-01 | Euro Celtique Sa | Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol |
TWI366460B (en) * | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
US8735374B2 (en) * | 2009-07-31 | 2014-05-27 | Intelgenx Corp. | Oral mucoadhesive dosage form |
KR101701203B1 (ko) * | 2014-10-16 | 2017-02-01 | 부경대학교 산학협력단 | 초임계이산화탄소를 이용한 퍼아세틸레이티드 사이클로덱스트린 및 약물의 포접체 초미립자, 이의 제조방법 및 이의 용도 |
US9398974B1 (en) * | 2015-02-10 | 2016-07-26 | Eddy H. delRio | Bruxism sensor |
AU2017210319A1 (en) * | 2016-01-20 | 2018-08-23 | Flurry Powders, Llc | Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation |
WO2017223519A1 (en) * | 2016-06-24 | 2017-12-28 | Cool Clean Technologies, Llc | Liquid carbon dioxide botanical extraction system |
NL2018190B1 (en) * | 2017-01-18 | 2018-07-26 | Procare Beheer B V | Psilocybin or psilocin in combination with cannabinoid |
EA202090890A1 (ru) * | 2017-10-05 | 2020-09-03 | Ресептор Холдингз, Инк. | Состав растительного и синтетического каннабиноида быстрого начала действия и пролонгированного действия |
CN109985042A (zh) * | 2017-12-29 | 2019-07-09 | 汉义生物科技(北京)有限公司 | 一种含有大麻二酚或大麻提取物和咖啡因的组合物及其应用 |
US10851077B2 (en) * | 2018-02-07 | 2020-12-01 | World Class Extractions Inc. | Method for extracting compositions from plants |
CN110123876A (zh) * | 2019-05-30 | 2019-08-16 | 汉义生物科技(北京)有限公司 | 一种含有非精神活性大麻素的包合物及其制备方法 |
-
2020
- 2020-10-21 IL IL292404A patent/IL292404A/en unknown
- 2020-10-21 KR KR1020227014983A patent/KR20220110730A/ko not_active IP Right Cessation
- 2020-10-21 US US17/768,132 patent/US20220387339A1/en active Pending
- 2020-10-21 JP JP2022538055A patent/JP7444995B2/ja active Active
- 2020-10-21 CA CA3158415A patent/CA3158415A1/en active Pending
- 2020-10-21 CN CN202080073887.0A patent/CN114630658A/zh active Pending
- 2020-10-21 MX MX2022004738A patent/MX2022004738A/es unknown
- 2020-10-21 WO PCT/US2020/056731 patent/WO2021081140A1/en unknown
- 2020-10-21 KR KR1020227014296A patent/KR20220084304A/ko unknown
- 2020-10-21 AU AU2020370165A patent/AU2020370165A1/en active Pending
- 2020-10-21 WO PCT/US2020/056729 patent/WO2021081138A1/en unknown
- 2020-10-21 CN CN202080073860.1A patent/CN115003288A/zh active Pending
- 2020-10-21 BR BR112022007605A patent/BR112022007605A2/pt unknown
- 2020-10-21 AU AU2020370166A patent/AU2020370166B2/en active Active
- 2020-10-21 BR BR112022007601A patent/BR112022007601A2/pt unknown
- 2020-10-21 CA CA3158416A patent/CA3158416C/en active Active
- 2020-10-21 EP EP20878320.9A patent/EP4048242A1/en active Pending
- 2020-10-21 EP EP20878459.5A patent/EP4048243A1/en active Pending
- 2020-10-21 JP JP2022550656A patent/JP2022554420A/ja active Pending
- 2020-10-21 MX MX2022004735A patent/MX2022004735A/es unknown
- 2020-10-21 IL IL292377A patent/IL292377B2/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004511530A (ja) | 2000-10-19 | 2004-04-15 | セパレックス | ホスト分子に包接された活性成分からなる微細粒子の製造方法 |
US20050153931A1 (en) | 2002-02-20 | 2005-07-14 | Pedipharm Oy | Novel natural cyclodextrin complexes |
JP2006524670A (ja) | 2003-04-25 | 2006-11-02 | ピエール、ファーブル、メディカマン | 分子複合体の調製のための方法 |
JP2010505605A (ja) | 2006-10-06 | 2010-02-25 | ニューサウス イノベーションズ ピーティーワイ リミテッド | 粒子の形成 |
JP2010522730A (ja) | 2007-03-28 | 2010-07-08 | ピエール ファーブル メディカモン | イブプロフェン、シクロデキストリンと第3の作用物質の錯体、および薬学におけるその利用方法 |
US20190038995A1 (en) | 2017-01-19 | 2019-02-07 | Metamorphic Alchemy & Distillations, Inc. | Method for removing contaminants from cannabinoid distillates |
Non-Patent Citations (2)
Title |
---|
Chem. Eur. J.,2016年,22,pp.2972-2979 |
Pharmaceutical Research,1999年,16(12),pp.1864-1870 |
Also Published As
Publication number | Publication date |
---|---|
CN115003288A (zh) | 2022-09-02 |
CN114630658A (zh) | 2022-06-14 |
IL292377B1 (en) | 2023-07-01 |
AU2020370165A1 (en) | 2022-04-21 |
MX2022004735A (es) | 2022-08-04 |
IL292404A (en) | 2022-06-01 |
KR20220084304A (ko) | 2022-06-21 |
IL292377A (en) | 2022-06-01 |
CA3158416A1 (en) | 2021-04-29 |
EP4048243A1 (en) | 2022-08-31 |
JP2022545986A (ja) | 2022-11-01 |
IL292377B2 (en) | 2023-11-01 |
JP2022554420A (ja) | 2022-12-28 |
KR20220110730A (ko) | 2022-08-09 |
BR112022007605A2 (pt) | 2022-10-04 |
MX2022004738A (es) | 2022-08-04 |
WO2021081140A1 (en) | 2021-04-29 |
CA3158415A1 (en) | 2021-04-29 |
US20220387339A1 (en) | 2022-12-08 |
BR112022007601A2 (pt) | 2022-10-04 |
AU2020370166A1 (en) | 2022-04-21 |
AU2020370166B2 (en) | 2022-05-19 |
EP4048242A1 (en) | 2022-08-31 |
WO2021081138A1 (en) | 2021-04-29 |
CA3158416C (en) | 2023-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7444995B2 (ja) | 超微粒化合物およびその製造 | |
EP2844243B1 (en) | Method for preparing a cannabis plant isolate comprising delta-9-tetrahydrocannabinol | |
US11801278B2 (en) | Method for obtaining an extract of a plant biomass | |
WO2019104442A1 (en) | Liquid dosage forms, methods of making and use | |
WO2020107119A1 (en) | Compositions comprising a cannabinoid or a cannabis-derived compound, methods of making and use | |
US20220265743A1 (en) | Protein based cannabis compositions | |
WO2020168421A1 (en) | Cyclodextrin inclusion complexes of cannabis extracts | |
WO2019211771A1 (en) | Water soluble and water dispersible formulations of cannabinoids | |
EP4168900A1 (en) | Compositions for supplementing products with therapeutic agents and methods of use thereof | |
WO2020161715A1 (en) | Cannabinoid containing composition, methods of preparation and use thereof | |
Visht et al. | Effect of Cholesterol and Different Solvents on Particle Size, Zeta Potential and Drug Release of Eucalyptus Oil Phytosome | |
US11857589B2 (en) | Water-soluble, powdered cannabinoid and/or terpene extract | |
WO2023067509A1 (en) | Compositions for supplementing kombucha products with therapeutic agents and methods of making and use thereof | |
WO2021252484A1 (en) | Compositions for the delivery of therapeutic agents and methods of use and making thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220617 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220617 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20220617 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221108 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230508 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230620 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230914 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231219 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240130 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240222 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7444995 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |